(Q44857539)

6 December 2017

title

Oseltamivir Dosing in Critically Ill Patients With Severe Influenza (English)

1 reference

6 December 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Melissa L Thompson Bastin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

9 May 2014

1 reference

Annals of Pharmacotherapy

6 December 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1011-1018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24816209%20AND%20SRC:MED&resulttype=core&format=json

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Pharmacokinetics of high-dose oseltamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362

End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014535362